Plonmarlimab, a GM-CSF-neutralizing antibody, for macrophage activation syndrome

This publication has 11 references indexed in Scilit:

• Hemophagocytic Lymphohistiocytosis
  New England Journal of Medicine, 2025
• Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease
  Annals of the Rheumatic Diseases, 2024
• EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease
  Annals of the Rheumatic Diseases, 2024
• Plonmarlimab, a novel anti‐GM‐CSF blocking antibody, ameliorates disease progression in the pre‐clinical model of macrophage activation syndrome
  Immunology, 2024
• Efficacy and safety of emapalumab in macrophage activation syndrome
  Annals of the Rheumatic Diseases, 2023
• The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis/macrophage activation syndrome – a systematic review
  Clinical and Experimental Immunology, 2020
• Genetic Deficiency of Interferon‐γ Reveals Interferon‐γ–Independent Manifestations of Murine Hemophagocytic Lymphohistiocytosis
  Arthritis & Rheumatology, 2019
• Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome
  Blood, 2018
• GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation
  Immunity, 2016
• Macrophage activation syndrome in the era of biologic therapy
  Nature Reviews Rheumatology, 2016